Literature DB >> 18698874

CNS adverse events associated with antiepileptic drugs.

Gina M Kennedy1, Samden D Lhatoo.   

Abstract

A variety of newer antiepileptic drugs (AEDs) are now available for treating patients with epilepsy in addition to the 'conventional' drugs that have been available throughout a large part of the last century. Since these drugs act to suppress the pathological neuronal hyperexcitability that constitutes the final substrate in many seizure disorders, it is not surprising that they are prone to causing adverse reactions that affect the CNS.Information on adverse effects of the older AEDs has been mainly observational. Equally, whilst the newer drugs have been more systematically studied, their long-term adverse effects are not clearly known. This is illustrated by the relatively late emergence of the knowledge of visual field constriction in the case of vigabatrin, which only became known after several hundred thousand patient-years of use. However, older drugs continue to be studied and there has been more recent comment on the possible effect of valproate (valproic acid) on cognition following exposure to this drug in utero.With most AEDs, there are mainly dose-related adverse effects that could be considered generic, such as sedation, drowsiness, incoordination, nausea and fatigue. Careful dose titration with small initial doses can reduce the likelihood of these adverse effects occurring. Adverse effects such as paraesthesiae are more commonly reported with drugs such as topiramate and zonisamide that have carbonic anhydrase activity. Weight loss and anorexia can also be peculiar to these drugs. Neuropsychiatric adverse effects are reported with a variety of AEDs and may not be dose related. Some drugs, such as carbamazepine when used to treat primary generalized epilepsy, can exacerbate certain seizure types. Rare adverse effects such as hyperammonaemia with valproate are drug specific. There are relatively very few head-to-head comparisons of AEDs and limited information is available in this regard.In this review, we discuss the available literature and provide a comprehensive summary of adverse drug reactions of AEDs affecting the CNS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18698874     DOI: 10.2165/00023210-200822090-00003

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  180 in total

1.  Tiagabine: efficacy and safety in adjunctive treatment of partial seizures.

Authors:  P Crawford; H Meinardi; S Brown; T W Rentmeester; B Pedersen; P C Pedersen; L C Lassen
Journal:  Epilepsia       Date:  2001-04       Impact factor: 5.864

Review 2.  Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies?

Authors:  G Zaccara; A Messori; M Cincotta; G Burchini
Journal:  Acta Neurol Scand       Date:  2006-09       Impact factor: 3.209

3.  The new antiepileptic drugs: a systematic review of their efficacy and tolerability.

Authors:  A G Marson; Z A Kadir; J L Hutton; D W Chadwick
Journal:  Epilepsia       Date:  1997-08       Impact factor: 5.864

4.  The use of clonazepam as an anticonvulsant--clinical evaluation.

Authors:  P F Bladin
Journal:  Med J Aust       Date:  1973-04-07       Impact factor: 7.738

5.  Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone.

Authors:  D B Smith; R H Mattson; J A Cramer; J F Collins; R A Novelly; B Craft
Journal:  Epilepsia       Date:  1987       Impact factor: 5.864

6.  Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases.

Authors:  K Masmoudi; V Gras-Champel; H Masson; M Andréjak
Journal:  Pharmacopsychiatry       Date:  2006-01       Impact factor: 5.788

7.  In utero exposure to phenobarbital and intelligence deficits in adult men.

Authors:  J M Reinisch; S A Sanders; E L Mortensen; D B Rubin
Journal:  JAMA       Date:  1995-11-15       Impact factor: 56.272

8.  Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group.

Authors:  F Matsuo; D Bergen; E Faught; J A Messenheimer; A T Dren; G D Rudd; C G Lineberry
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

9.  Controlled trial of lamotrigine (Lamictal) for refractory partial seizures.

Authors:  S Jawad; A Richens; G Goodwin; W C Yuen
Journal:  Epilepsia       Date:  1989 May-Jun       Impact factor: 5.864

10.  Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial.

Authors:  J Messenheimer; R E Ramsay; L J Willmore; R F Leroy; J J Zielinski; R Mattson; J M Pellock; A M Valakas; G Womble; M Risner
Journal:  Epilepsia       Date:  1994 Jan-Feb       Impact factor: 5.864

View more
  17 in total

Review 1.  Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series.

Authors:  Nancy J Butcher; Erik Boot; Anthony E Lang; Danielle Andrade; Jacob Vorstman; Donna McDonald-McGinn; Anne S Bassett
Journal:  Am J Med Genet A       Date:  2018-05-19       Impact factor: 2.802

2.  Outcomes after discontinuation of antiepileptic drugs after surgery in patients with low grade brain tumors and meningiomas.

Authors:  Rohit R Das; Elinor Artsy; Shelley Hurwitz; Patrick Y Wen; Peter Black; Alexandra Golby; Barbara Dworetzky; Jong Woo Lee
Journal:  J Neurooncol       Date:  2012-01-03       Impact factor: 4.130

Review 3.  Safety and tolerability of antiepileptic drug treatment in children with epilepsy.

Authors:  Renzo Guerrini; Gaetano Zaccara; Giancarlo la Marca; Anna Rosati
Journal:  Drug Saf       Date:  2012-07-01       Impact factor: 5.606

4.  Design, synthesis, and pharmacological evaluation of [1, 3] dioxolo-chromeno[2,3-b]pyridines as anti-seizure agents.

Authors:  Visarapu Malathi; Nissi Sharon; Pannala Padmaja; Deepak Lokwani; Saurabh Khadse; Prashant Chaudhari; Atul A Shirkhedkar; Pedavenkatagari Narayana Reddy; Vinod G Ugale
Journal:  Mol Divers       Date:  2022-10-10       Impact factor: 3.364

Review 5.  Topiramate and cognitive impairment: evidence and clinical implications.

Authors:  Marco Mula
Journal:  Ther Adv Drug Saf       Date:  2012-12

Review 6.  Biological approaches to aphasia treatment.

Authors:  Steven L Small; Daniel A Llano
Journal:  Curr Neurol Neurosci Rep       Date:  2009-11       Impact factor: 5.081

7.  Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery.

Authors:  Graham Powell; Emily A F Holmes; Catrin O Plumpton; Adele Ring; Gus A Baker; Ann Jacoby; Munir Pirmohamed; Anthony G Marson; Dyfrig A Hughes
Journal:  Br J Clin Pharmacol       Date:  2015-08-22       Impact factor: 4.335

8.  Clinical outcomes and immune benefits of anti-epileptic drug therapy in HIV/AIDS.

Authors:  Kathy Lee; Pornpun Vivithanaporn; Reed A Siemieniuk; Hartmut B Krentz; Ferdinand Maingat; M John Gill; Christopher Power
Journal:  BMC Neurol       Date:  2010-06-17       Impact factor: 2.474

9.  Synthesis of Novel 7-Substituted-5-phenyl-[1,2,4]triazolo[1,5-a] Pyrimidines with Anticonvulsant Activity.

Authors:  Nan Jiang; Xian-Qing Deng; Fu-Nan Li; Zhe-Shan Quan
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

Review 10.  Psychotropic treatments in Prader-Willi syndrome: a critical review of published literature.

Authors:  O Bonnot; D Cohen; D Thuilleaux; A Consoli; S Cabal; M Tauber
Journal:  Eur J Pediatr       Date:  2015-11-19       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.